Justice Ketanji Brown Jackson authored a unanimous Supreme Court decision Thursday in a patent dispute between a brand-name drugmaker and a generic competitor, a 9-0 ruling that united all six conservative justices behind the liberal Biden appointee's legal reasoning.
The case, Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., turned on a narrow but consequential question: when can a brand-name pharmaceutical company sue a generic rival for allegedly encouraging doctors to prescribe a drug for a patented use the generic maker claims it carved off its label?
The Court reversed the U.S. Court of Appeals for the Federal Circuit and sent the case back for further proceedings, clarifying the legal standard that governs so-called "skinny label" disputes under the Hatch-Waxman Act. That federal law sets the rules for competition between brand-name and generic drugs, a framework that shapes how quickly cheaper alternatives reach patients and pharmacies across the country.
At the center of the dispute is Vascepa, a prescription fish-oil drug first approved in 2012 to treat severe hypertriglyceridemia. Vascepa later gained a second, broader approval for reducing cardiovascular risk in a much larger patient population. Amarin Pharma, the drugmaker behind Vascepa, holds the patent on that cardiovascular use.
Hikma Pharmaceuticals sought to bring a generic version of Vascepa to market using a "skinny label", a common regulatory strategy in which a generic maker lists only the non-patented uses on its packaging, carving out the patented indication. Amarin sued, alleging that Hikma's marketing amounted to inducing patent infringement by encouraging physicians to prescribe the drug for the protected cardiovascular use.
A federal district court dismissed the case. The Federal Circuit reversed, finding Amarin's allegations plausible enough to proceed. The Supreme Court then took up the question of what legal standard should apply.
Jackson's opinion, joined by every member of the Court, held that the proper test centers on whether a generic drugmaker engaged in "active encouragement" of the patented use. The decision did not resolve the underlying facts. Instead, it clarified the framework lower courts must apply when evaluating these induced-infringement claims, and sent the case back down for that analysis.
The 9-0 outcome is notable in a term defined by sharp ideological fractures. High-profile Supreme Court rulings often break 6-3 along predictable lines, with the Court's three liberal justices on one side and the six conservative appointees on the other. Jackson writing for all nine justices on a question of patent law and pharmaceutical competition cuts against that pattern.
It is not the first time this term that Jackson has drawn unanimous support. Earlier this year, she authored another 9-0 decision in Urias-Orellana v. Bondi. But the broader picture of her term is more complicated.
Supreme Court term statistics show Jackson was in the majority in roughly 72 percent of cases during the 2024, 25 term, the lowest rate of any justice, as Newsweek reported. That figure reflects how often she has found herself on the losing side of contested rulings this term, particularly in cases that split along ideological lines.
Just last week, Jackson issued a lone dissent in Fernandez v. United States, an 8-1 ruling. In that case, she argued the majority took too narrow a view of compassionate release as a pathway for relief, a position that not even fellow liberal justices Elena Kagan and Sonia Sotomayor joined. That kind of solo break from her own ideological wing is unusual and has drawn attention to Jackson's willingness to separate from Kagan and Sotomayor on certain questions.
The ruling carries real consequences beyond the courtroom. Generic drugs account for the vast majority of prescriptions filled in the United States. A 2026 analysis published in the medical journal JAMA described timely competition from generics as "the single most important mechanism for lowering prescription drug spending in the U.S."
The legal standard the Court clarified Thursday will shape how aggressively brand-name drugmakers can use induced-infringement claims to block or delay generic competitors that use skinny labels. A more permissive standard could expose generic manufacturers to greater litigation risk, potentially discouraging market entry. A tighter standard could make it harder for patent holders to protect their exclusivity.
By sending the case back rather than resolving it outright, the Court left the practical outcome for Hikma and Amarin unresolved. Lower courts will now apply the "active encouragement" framework Jackson outlined. How they interpret the facts on remand will determine whether Amarin's infringement claims survive, and whether Hikma's generic Vascepa reaches the market on the terms it proposed.
The Hikma ruling is a reminder that the Supreme Court's work extends well beyond the culture-war cases that dominate cable news. Patent law, regulatory frameworks, and pharmaceutical competition rarely generate headlines, but they affect drug prices, market access, and the legal ground rules for an industry that touches every American household.
This term has produced its share of fractured decisions. The Court split 5-4 in a Mississippi death-row case over jury selection, and ideological tensions have surfaced in disputes involving executive power and federal regulation. But cases like Hikma show that when the legal question is technical enough and the reasoning sufficiently grounded in statutory text, the justices can still reach consensus.
Jackson's authorship of two unanimous opinions this term complicates any simple narrative about her role on the bench. She remains the justice most often in dissent during the 2024-25 term. Yet on questions of statutory interpretation, where the ideological stakes are lower and the textual analysis more straightforward, she has demonstrated an ability to write opinions that satisfy originalists and progressives alike.
The broader Court has shown similar complexity. Conservative justices have broken from expected alignments on tariff and executive-power questions this term, and unusual coalitions have formed in cases involving federal agency authority. The 9-0 lineup in Hikma fits that pattern, a Court that, for all its well-documented divisions, still finds common ground when the law points clearly in one direction.
Unanimity at the Supreme Court doesn't make for exciting television. But it's how the institution is supposed to work, nine justices reading the same statute and arriving at the same answer. The country could use more of it.